These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 15239487)

  • 1. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways.
    Turley SD
    Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III16-21. PubMed ID: 15239487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe: rationale and role in the management of hypercholesterolemia.
    Yatskar L; Fisher EA; Schwartzbard A
    Clin Cardiol; 2006 Feb; 29(2):52-5. PubMed ID: 16506638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis].
    Paragh G; Márk L; Czine Z
    Orv Hetil; 2004 Apr; 145(15):805-11. PubMed ID: 15188635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
    Grigore L; Norata GD; Catapano AL
    Vasc Health Risk Manag; 2008; 4(2):267-78. PubMed ID: 18561502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.
    Davis HR; Veltri EP
    J Atheroscler Thromb; 2007 Jun; 14(3):99-108. PubMed ID: 17587760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art in cholesterol management: targeting multiple pathways.
    Turley SD
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S29-32; discussion S45-7. PubMed ID: 11855699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing lipid lowering in patients at risk.
    Clark LT
    Clin Cardiol; 2004 Jun; 27(6 Suppl 3):III22-6. PubMed ID: 15239488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ezetimibe--intestinal cholesterol absorbtion inhibitor].
    Pikto-Pietkiewicz W; Pasierski T
    Kardiol Pol; 2006 Dec; 64(12):1434-41. PubMed ID: 17206545
    [No Abstract]   [Full Text] [Related]  

  • 12. Ezetimibe (Schering-Plough).
    Meng CQ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):389-92. PubMed ID: 11575710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ezetimibe: from pharmacology to clinical trials].
    Tellier P
    Ann Endocrinol (Paris); 2003 Dec; 64(6):442-7. PubMed ID: 15067249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.
    Pisciotta L; Fasano T; Bellocchio A; Bocchi L; Sallo R; Fresa R; Colangeli I; Cantafora A; Calandra S; Bertolini S
    Atherosclerosis; 2007 Oct; 194(2):e116-22. PubMed ID: 17140581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways.
    Patel SB
    Curr Cardiol Rep; 2004 Nov; 6(6):439-42. PubMed ID: 15485605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].
    Márk L; Paragh G
    Orv Hetil; 2007 Apr; 148(14):627-32. PubMed ID: 17403635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe.
    Bays H
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1587-604. PubMed ID: 12437505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.